Skip to main content

Assessment of ARIA Sufficiency: Bimzelx (bimekizumab-bkzx)

    Basic Details
    Approval Date
    Tuesday, October 17, 2023
    Original Posting Date
    Health Outcome(s)
    adverse pregnancy and fetal outcomes
    drug induced liver injury
    hematologic adverse reactions
    hepatitis B reactivation
    hypersensitivity reactions
    inflammatory bowel disease (IBD)
    major adverse cardiovascular events
    opportunistic infections
    serious infections
    tuberculosis (TB)